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Background: Despite the downward trend in the absolute number of tuberculosis (TB) cases since 2006 and the
fall in the incidence rates since 2001, the burden of disease caused by TB remains a global health challenge. The
co-infection between TB and HIV adds to this disease burden. TB is completely curable through the intake of a
strict anti-TB drug treatment regimen which requires an extremely high and consistent level of adherence.The aim
of this study was to investigate factors associated with adherence to anti-TB and HIV treatment drugs.
Methods: A cross-sectional survey method was used. Three study districts (14 primary health care facilities in each)
were selected on the basis of the highest TB caseload per clinic. All new TB and new TB retreatment patients were
consecutively screened within one month of anti-tuberculosis treatment. The sample comprised of 3107 TB patients
who had been on treatment for at least three weeks and a sub-sample of the total sample were on both anti-TB
treatment and anti-retro-viral therapy(ART) (N = 757). Data collection tools included: a Socio-Demographic
Questionnaire; a Post-Traumatic-Stress-Disorder (PTSD) Screen; a Psychological Distress Scale; the Alcohol Use
Disorder Identification Test (AUDIT); and self-report measures of tobacco use, perceived health status and
adherence to anti-TB drugs and ART.
Results: The majority of the participants (N = 3107) were new TB cases with a 55.9% HIV co-infection rate in this
adult male and female sample 18 years and older. Significant predictors of non-adherence common to both anti-TB
drugs and to dual therapy (ART and anti-TB drugs) included poverty, having one or more co-morbid health
condition, being a high risk for alcohol mis-use and a partner who is HIV positive. An additional predictor for
non-adherence to anti-TB drugs was tobacco use.
Conclusions: A comprehensive treatment programme addressing poverty, alcohol mis-use, tobacco use and
psycho-social counseling is indicated for TB patients (with and without HIV). The treatment care package needs to
involve not only the health sector but other relevant government sectors, such as social development.
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Despite the downward trend in the absolute number of
TB cases since 2006 and the fall in the incidence rates
since 2001, the burden of tuberculosis (TB) disease re-
mains a global health challenge [1]. TB is completely cur-
able through the intake of a strict drug treatment
regimen. The Directly Observed Treatments Short-
Course Strategy (DOTS) introduced by the World Health
Organization (WHO) and subsequently the Stop TB
Strategy is an inexpensive strategy that could prevent
millions of TB cases and deaths. TB/HIV co-infection
and multi-drug resistant (MDR)/ extensive drug-resistant
(XDR)TB are given focal attention in the Stop TB Strat-
egy and one of its primary TB targets is to reduce by half
the TB prevalence rates by 2015 relative to 1990 [1].
The HIV and AIDS pandemics have exacerbated the
public health dimensions of TB due to the fact that
many individuals are co-infected. TB is the leading cause
of death among people who are HIV positive. In the
African region, which accounted for 82% of the new TB
cases that were also HIV positive, an estimated 900 000
(39%) of the 2.3 million people who developed TB were
living with HIV [1].
Adherence to anti-TB treatment and to treatment for
HIV/TB co-infection
Poor adherence to the prescribed anti-TB treatment
programmes, such as those falling under the DOTS strat-
egy, is one of the factors associated with low cure rates for
TB. In addition, inconsistent adherence to the anti-TB drug
regimen may lead to multiple and extensive drug resistance
(MDR-TB and XDR-TB respectively) making it difficult to
achieve high cure rates. In individuals with TB/HIV dual
infection receiving treatment, correct adherence to anti-TB
drugs and anti-retroviral therapy (ART) are essential for
good treatment outcomes [2]. Poor and inconsistent adher-
ence to ART can also lead to drug resistance and even
death, an outcome which is similar to non-adherence to
anti-TB drugs [2,3].
The categories of factors influencing adherence to
drug treatments for most health-related conditions, in-
clude: practitioner’s negative assumptions about their
patients; psychological attributes of the patient; environ-
mental, social and cultural factors; treatment character-
istics; and the doctor–patient relationship [3,4]. Many
quantitative and qualitative studies conducted in South
Africa (SA) have identified factors known to influence
adherence to anti-TB treatment [5-7]. Qualitative studies
exploring adult TB patient’s adherence to anti-TB treat-
ment at public health sites in SA found that the factors
that influenced patient co-operation included: social and
economic resources; causal attributions assigned to TB;
the social, cultural, economic, disease-related and psy-
chological challenges faced as a consequence of havingTB; quality of health care received; use of the traditional
healing system; and the patient’s HIV status [5,7]. Quan-
titative studies examining the factors that influence
adherence to anti-TB treatment regimens found the fol-
lowing to be important: a good patient–practitioner rela-
tionship, ability of the patient to disclose medication use
to members of their social network and regular clinic
visits [8,9].
Numerous studies have also been conducted in Africa
and globally on factors influencing adherence to anti-TB
treatment and adherence to the dual treatment approach
for TB and HIV [2,10,11]. A systematic review of quali-
tative research, exploring patient adherence to tubercu-
losis treatment, conducted by Munro et al found that
the following four factors interact to affect adherence to
TB treatment: structural factors, including poverty and
gender discrimination; the social context; health service
factors and personal factors [5]. An African-based quali-
tative study which explored barriers and facilitators of
adherence to anti-TB treatment and concomitant TB
and HIV treatment in Ethiopia, found that adherence to
TB treatment was positively influenced by beliefs in the
curability of TB, beliefs in the severity of TB in the pres-
ence of HIV infection and support from family members
and health professionals [11].
A systematic review done on studies conducted in the
US and Canada on adherence to treatment for latent tu-
berculosis infection found that there was a “sub-optimal”
level of adherence indicated across all studies [12]. The
factors influencing adherence were clinic facilities, treat-
ment characteristics and patient factors although the as-
sociation between adherence and these factors was found
to be inconsistent [12]. Adherence to ARVs as compared
to anti-TB drugs is, however, reported to be high the
world over and Corless et al based a quantitative study
conducted in clinics in Durban, SA, on this premise [10].
They found that in fact adherence to ARVs in their study
was also high [10]. Amuha et al found that the most im-
portant factor associated with non-adherence to anti-TB
medication in individuals co-infected with HIV was being
on a continuous treatment regimen phase as compared
to the intensive treatment phase. Confounding factors in-
fluencing the association between the stage of the TB
regimen and non-adherence were alcohol consumption,
being on ARVs and smoking [13]. The exact nature of
these confounding factors and its influence on non-
adherence has not been interrogated.
Relatively few studies have looked specifically at the
sub-group of individuals on anti-TB treatment who also
meet the criteria for alcohol use disorders in South
Africa (SA). This study forms part of a larger study en-
titled: Screening and brief interventions for hazardous
and harmful alcohol use among patients with active tu-
berculosis attending primary public care clinics in SA.
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ture to confirm that TB medication non-adherence is
associated with the use and mis-use of alcohol [14,15].
In SA, however, the association between alcohol (mis)
use and non-adherence to anti-TB treatment and dual
therapy in those individuals co-infected with HIV has
been not been adequately studied. In addition, the way
in which individual mental health risk factors, such as
distress and post-traumatic stress, mediate TB and TB/
HIV health outcomes for individuals mis-using alcohol,
has been neglected.
The value of this study is that it used a different meth-
odology to most other TB treatment adherence studies.
The study uses different questionnaires (such as the
measures of distress and PTSD) and different outcome
measures (namely, adherence to anti-TB treatment, and
adherence to ART and anti TB treatment (dual therapy)
as compared to other adherence studies. Consequently,
the primary aim of this study, using base-line data was
to investigate the factors that are associated with non-
adherence to anti-TB drugs for those with active TB and
to ART and anti-TB drugs taken by individuals who have
dual infection. The secondary aim, which also addresses
a gap in research, was to specifically investigate the sig-
nificance of alcohol misuse as a predictive factor for
non-adherence to anti-TB drugs and to dual therapy
(namely, anti-TB drugs and ART).
Methods
Study design, sample and procedure
This study is a cross-sectional survey. Fourteen (14)
public primary health care clinics in only one district
in each of three provinces, namely, Northern Cape,
Eastern Cape and Kwa-Zulu Natal in SA with the
highest TB caseload were included in the study. All
new TB and new retreatment patients were consecu-
tively screened within one month of anti-TB treat-
ment. The public primary health care clinics that
were utilized in this study followed the SA Depart-
ment of Health’s (DoH) Guidelines for TB treatment
who in turn are guided by the WHOs TB treatment
guidelines framed by the Stop TB strategy which
strongly recommends the DOT programme [16]. The
DOT programme requires intensive involvement and
monitoring by the clinic staff but the treatment suc-
cess is also dependent on the patient adhering strictly
to the treatment guidelines. In this study a total of
3129 potential participants were screened and 22
(0.7%) refused to participate. It was not necessary to
perform an attrition analysis due to the good response
rate. In the data analysis the total sample size used
was 3107 participants (N = 3107). All the participants’
in this study were taking anti-TB treatment for at
least three weeks, which fell into the intensive phaseof the DOTS programme which required them to at-
tend the clinic during the week and take their anti-TB
drugs dose at their homes over the week-end.
Within the larger sample there was a sub-sample of
patients who were HIV positive (N = 1729) and a pro-
portion of the HIV positive patients (44%) who were on
ART (N = 757).
A screening interview was conducted by trained re-
search assistants over a period of six (6) months in 2011.
A health care provider who identified a new TB treat-
ment or retreatment patient 18 years and above informed
the patient about the study and referred the patient for
participation if they were willing. A consenting procedure
was adopted prior to the start of the screening interview.
Ethical approval was received from the Human Sciences
Research Council Research Ethics Committee (Protocol
REC No.1/16/02/11) and the Department of Health
(DoH) in SA.
Data collection tools
The data collection tools specified in this section was
administered to all the participants in this study.
Socio-demographic questionnaire
A researcher-designed questionnaire was used to record
information on participants’ age, gender, educational
level, marital status, income, employment status, dwell-
ing characteristics and residential status. Using a previ-
ously designed questionnaire, which is also extensively
used in the Human Sciences Research Council (HSRC_SA)
national health surveys, poverty was assessed by five (5)
pertinent items on the questionnaire by asking about the
availability or non-availability of shelter, fuel or electricity,
clean water, food and cash income in the past week
[17]. Response options ranged from 1 = “Not one day”
to 4 = “Every day of the week”. Participants ranked high on
poverty if they had higher scores on non-availability of es-
sential items. The total poverty score ranged from 5 to 20
with the following categories: 5 indicating low poverty; 6 to
12 indicating a medium level of poverty; and 13 to 20 indi-
cating high levels of poverty. The Cronbach alpha for the
poverty index in this study was fairly good (0.89).
The Kessler Psychological Distress Scale (K-10)
The Kessler Psychological Distress Scale (K-10) was
used to measure global psychological distress [18,19].
The K-10 measures the following symptoms over the
preceding 30 days: nervousness, hopelessness, restless-
ness, depression, worthlessness and tiredness. The fre-
quency with which each of these items was experienced
was recorded using a five-point Likert scale ranging from
“none of the time” to “all the time”. Increasing total
scores reflect an increasing degree of psychological dis-
tress. The K-10 has been shown to capture variability
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abuse [19]. This scale serves to identify individuals who
are likely to meet formal definitions for anxiety and/or
depressive disorders, as well as to identify individuals
with sub-clinical illness who may not meet formal defini-
tions for a specific disorder [18]. This scale is increasingly
used in population based mental health research and has
been validated in multiple settings [20,21] including HIV
positive individuals in SA [22]. The internal reliability co-
efficient for the K-10 in this study was alpha = 0.92 which
is fairly high.
Alcohol consumption
The 10-item Alcohol Use Disorder Identification Test
(AUDIT) [23] assesses alcohol consumption level, symp-
toms of alcohol dependence and problems associated with
alcohol use. The AUDIT largely measures heavy episodic
drinking with only one (1) item measuring binge drinking.
Heavy episodic drinking is defined as the consumption of
six standard drinks or more on a single occasion. A stand-
ard drink in this instance is 10 g of alcohol. In SA a stand-
ard drink is 12 g of alcohol and not 10 g. The AUDIT is
reported to be less sensitive at identifying risk drinking in
women [24] so it was recommended that the cut-off point
for the binge drinking measure is reduced by one (1) unit
among women in SA and the overall heavy episodic drink-
ing measure is also reduced due to the fact that a standard
drink is 12 g of alcohol (and not 10 g as stipulated by the
AUDIT). Responses to items on the AUDIT are rated on a
four-point-Likert scale from 0 to 4, for a maximum score
of 40 points. A cut off score of 8 indicates a tendency to
problematic drinking. The AUDIT was developed by the
WHO as an effective screening instrument for alcohol
use problems among patients seeking primary care for
other medical problems in international settings including
African countries (Kenya and Zimbabwe) [24-27]. The
AUDIT has been validated in HIV patients in SA showing
excellent sensitivity and specificity in detecting alcohol de-
pendence and alcohol abuse as defined on the Mini-
International Neuropsychiatric Interview (MINI) [26]. The
MINI is an internationally recognized diagnostic tool in
the form of a psychiatric interview.
The MINI used in a study of TB and HIV patients in pri-
mary care in Zambia also demonstrated good discrimin-
atory ability in detecting MINI-defined current Alcohol
Use Disorders (AUDs) (AUDIT = 0.98 for women and 0.75
for men) [27]. Cronbach alpha for the AUDIT in this sam-
ple was 0.92, indicating excellent reliability.
Additional self-report measures
(a) Tobacco use: Two researcher generated questions
were asked about the use of tobacco products. The
first question asked about current tobacco use andthe second question asked about the frequency of
use over the past month.
(b) Non-adherence to anti-TB treatment, non-adherence
to ART, and HIV testing: Adherence was assessed by
self-report. Whether a participant tested for HIV
infection was also assessed by self-report. Anti-TB
medication adherence was assessed with the following
question: “In your tuberculosis treatment in the past
3–4 weeks how many percent (%) of your anti-
tuberculosis medication did you take?” TB medication
non-adherence was defined as having taken less than
90% of the anti-TB drugs. Self-reporting adherence
behaviour over the past 3–4 week period for anti-TB
drugs was asked due to the fact that the participants
in this study were recruited only if they had started
their TB treatment at least three weeks before being
enrolled into the study.
ART adherence was assessed with the question:
“How many percent of your HIV medication did
you take in the past 4 weeks?” ART non-adherence
was defined as having taken less than 90% of ART.
In each instance, that is for both ART and anti-TB
treatment non-adherence, participants were
required to mark the percentage adherence on an
illustrated scale indicating progression from 0% to
100% adherence.
(c) Co-morbidity with other chronic medical conditions
including hypertension, diabetes, depression, stomach
ulcer, migraine headache, cancer, arthritis, asthma,
diabetes, cholesterol were also ascertained.
Data analysis
Data were analyzed using the Statistical Package for the So-
cial Sciences (SPSS-version 19). Frequencies, means, and
standard deviations, were calculated to describe the sam-
ple. Data were checked for normality distribution and out-
liers. For non-normal distribution non-parametric tests
were used. Associations between TB medication and ART
non-adherence were identified using logistics regression
analyses. Following each univariate regression, multivari-
able logistic regression models were constructed. A total of
574 participants were used in the multivariate analysis. In-
dependent variables from the univariate analyses were en-
tered into the multivariable model if significant at P < 0.05
level. For each model, the R2 are presented to describe
the amount of variance explained by the multivariable
model. Probability below 0.05 was regarded as statistically
significant.
Results
Characteristics of the final sample
Table 1 indicates that the sample included 671 (21.8%;
N = 3107) retreatment cases, 2408 (78.2%; N = 3107)
new TB cases and 55.6% HIV infected cases. A little
Table 1 Characteristics of the total sample of TB patients
and sub-sample of TB patients on ART
Socio-demographics Total TB patients
(N = 3107)
Total TB-ART
patients (N = 757)
N (%) N (%)
Age 18–24 416 (13.5) 65 (8.7)
Age 25–34 1160 (37.7) 283 (37.8)
Age 35–44 861 (28.0) 252 (33.7)
Age 45 and older 639 (20.8) 148 (19.8)
Missing N 31 9
Female 1427 (46.5) 387 (51.7)
Male 1639 (53.5) 362 (48.3)
Missing N 41 8
Grade 7 or less 774 (25.2) 234 (31.5)
Grade 8–11 1415 (16.1) 330 (44.4)
Grade 12 or more 881 (28.7) 179 (24.1)
Missing N 37 14
Poverty low 1052 (35.5) 173 (24.4)
Poverty medium 1484 (50.1) 377 (53.1)
Poverty high 427 (14.4) 160 (22.5)
Missing N 144 47
Health variables
Perceived health status
Excellent/Very good 573 (18.6) 217 (28.8)
Good 1089 (35.3) 231 (30.2)
Fair/Poor 1423 (46.1) 305 (40.5)
Unknown N 22 4
TB retreatment patient 671 (21.8) 224 (30.0)
New TB patient 2408 (78.2) 523 (70.0)
Unknown N 28 10
HIV positive 1729 (55.9)
HIV negative 1073 (34.5)
HIV unknown status 305 (9.8)
Chronic conditions
Zero 1983 (72.5) 422 (65.7)
One 443 (16.2) 112 (17.4)
Two 194 (7.1) 60 (9.3)
Three or more 117 (4.3) 48 (7.5)
Unknown N 370 115
Severe psychological distress
(K≥ 30)
776 (25.0) 208 (27.5)
Alcohol: low risk (AUDIT
0–7)
2392 (78.0) 599 (80.0)
Medium (AUDIT 8–19) 504 (16.4) 119 (15.9)
High (AUDIT 20–40) 172 (5.6) 31 (4.1)
Unknown N 39 8
Current tobacco use 799 (26.2) 203 (27.4)
Table 1 Characteristics of the total sample of TB patients
and sub-sample of TB patients on ART (Continued)
Partner HIV negative/
unknown
2061 (71.6) 436 (61.8)
Partner HIV positive 818 (28.4) 269 (38.2)
Unknown/missing N 228 (7.3) 52 (6.9)
Sex partner on ART 300 (11.8) 355 (48.8)
TB non-adherence 812 (26.1) 315 (41.6)
ART non adherence 321 (42.4)
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sample reported medium levels of poverty, about a third
(35.3%) good perceived health status with more partici-
pants (46.1%) reporting poor perceived health status.
Other characteristics of significance include the follow-
ing: 776 (25%) met the criteria for severe psychological
distress and 16.4% for the category of medium risk for
alcohol misuse on the AUDIT. Finally, 26.1% were non-
adherent to the anti-TB treatment (min = 0, max = 100,
mean = 77.0, median = 90.0, SD = 43.9).
A sub-sample (N = 757) of the total sample was on
dual anti-TB treatment and ART. The characteristics of
this group were as follows: the majority of participants
were between the ages of 25 and 44 years, half the sam-
ple reported medium levels of poverty, two-fifths (40.5%)
reported poor perceived health status, 15.9% were at the
medium risk category for alcohol misuse on the AUDIT,
38.2% had a partner who was HIV positive, and 42.4%
were non-adherent to ART (min = 0, max = 100, mean =
64.8, median = 100.0, SD = 43.9). Of a total of 268 partic-
ipants 83.8% were not adherent to both anti-TB and
ART medication (r = 0.71).
Predictors of non-adherence to TB treatment
Univariate analysis (see Table 2) shows that the follow-
ing factors were more likely to be associated with
non-adherence to TB treatment: being male [OR: 1.26
(1.07–1.48), p < 0.05], medium poverty [OR: 1.97 (1.62–
2.41), p < 0.001], high levels of poverty [OR: 4.01 (3.12–
5.10), p < 0.001], having one (1) chronic condition [OR:
1.54 (1.23–1.93), p < 0.001], having two (2) chronic
conditions [OR: 1.84 (1.34–2.51), p < 0.001], having
three or more chronic conditions [OR: 1.98 (1.34–
2.92), p < 0.001], severe psychological distress [OR: 1.31
(1.09–1.57), p < 0.01], medium risk for alcohol misuse
[OR: 1.74 (1.42–2.19), p < 0.001], high risk for alcohol
misuse [OR: 2.42 (1.76–3.32), p < 0.001], tobacco use
[OR: 2.09 (1.76–2.49), p < 0.001] and having a partner
who is HIV positive [OR: 1.43 (1.10–1.84), p < 0.01].
Univariate analysis (see Table 2) shows that the follow-
ing factors were more likely to be associated with adher-
ence to TB treatment: being in the 25–34 year age group
Table 2 Predictors of non-adherence to TB medication
(N = 3107)
Socio-demographics Crude OR
(95% CI)
Adjusted OR
(95% CI)a,b
Age 18–24 1.00 1.00
Age 25–34 0.76 (0.59–0.97)* 0.93 (0.65–1.32)
Age 35–44 0.77 (0.60–1.00) 1.00 (0.68–1.45)
Age 45 and older 0.80 (0.61–1.05) 0.65 (0.43–1.00)
Female 1.00 1.00
Male 1.26 (1.07–1.48)** 1.09 (0.86–1.38)
Grade 7 or less 1.00 1.00
Grade 8–11 0.88 (0.72–1.06) 1.07 (0.80–1.43)
Grade 12 or more 0.68 (0.55–0.85)*** 0.76 (0.54–1.07)
Poverty low 1.00 1.00
Poverty medium 1.97 (1.62–2.410*** 1.73 (1.34–2.24)***
Poverty high 4.01 (3.12–5.10)*** 1.65 (1.14–2.39)**
Health variables
Perceived health status
Excellent/Very good 1.00 1.00
Good 0.36 (0.29–0.45)*** 0.50 (0.37–0.67)***
Fair/Poor 0.24 (0.20–0.30)*** 0.44 (0.32–0.60)***
TB retreatment patient 1.00 –
New TB patient 0.82 (0.67–1.00)
HIV positive 1.00 1.00
HIV negative 0.40 (0.34–0.48)*** 0.44 (0.33–0.59)***
Chronic conditions
Zero 1.00 1.00
One 1.54 (1.23–1.93)*** 1.86 (1.41–2.46)***
Two 1.84 (1.34–2.51)*** 2.44 (1.68–3.56)***
Three or more 1.98 (1.34–2.92)*** 2.37 (1.45–3.88)***
Severe psychological distress
(K≥ 30)
1.31 (1.09–1.57)** 0.94 (0.73–1.22)
Alcohol: low risk (AUDIT 0–7) 1.00 1.00
Medium (AUDIT 8–19) 1.74 (1.42–2.19)*** 1.65 (1.23–2.29)***
High (AUDIT 20–40) 2.42 (1.76–3.32)*** 3.06 (1.94–4.81***
Current tobacco use 2.09 (1.76–2.49)*** 1.35 (1.04–1.75)*
On ART 0.70 (0.56–0.86)*** 0.78 (0.60–1.03)
Partner HIV negative/unknown 1.00 1.00
Partner HIV positive 1.41 (1.16–1.70)*** 1.43 (1.10–1.84)**
*P < 0.05; ** P < 0.01; *** P < 0.001.
aUsing “enter” LR selection of variables.
bHosmer and Lemeshow Chi-square 7.68, df8, 0.466; Cox and Snell R2 0.11;
Nagelkerke R2 0.16.
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more education [OR: 0.68 (0.55–0.85), p < 0.001], per-
ceiving health status as being ‘poor’ [OR: 0.24 (0.20–
0.30), p < 0.001], perceiving health status to be ‘good’
[OR: 0.36 (0.29–0.45), p < 0.001], being HIV negative[OR: 0.40 (0.34–0.48), p < 0.001], and being on ART [OR:
0.70 (0.56–0.86), p < 0.001].
Multivariable analysis (see Table 2) indicates that the
following factors are more likely to predict TB treat-
ment non-adherence: medium levels of poverty [OR:
1.73 (1.34–2.24), p < 0.001], high levels of poverty [OR:
1.65 (1.14–2.39), having one (1) chronic condition
[OR: 1.86 (1.41–2.46), p < 0.001], having two (2) chronic
conditions [OR: 2.44 (1.68–3.56), p < 0.001], having
three or more chronic conditions [OR: 2.37 (1.45–3.88),
p < 0.001], medium risk for alcohol misuse [OR: 1.65
(1.23–2.29), p < 0.001], high risk for alcohol misuse
[OR: 3.06 (1.94–4.81), p < 0.001], tobacco use [OR: 1.35
(1.04–1.75), p < 0.05], and having a partner who is HIV
positive [OR: 1.43 (1.10–1.84), p < 0.01].
Multivariable analysis (see Table 2) indicates that the
following factors are more likely to predict adherence to
TB treatment: perceiving health status as being ‘poor’
[OR: 0.44 (0.32–0.60), p < 0.001], perceiving health status
to be ‘good’ [OR: 0.50 (0.37–0.67), p < 0.001], and being
HIV negative [OR: 0.44 (0.33–0.59), p < 0.001].
Predictors of non-adherence to dual therapy (anti-TB
treatment and ART)
Univariate analysis (see Table 3) indicates that the variables
significantly associated with non-adherence to dual therapy
were: being male [OR: 1.61 (1.20–2.16), p < 0.001], being
in the medium poverty category [OR: 3.14 (2.05–4.79),
p < 0.001], being in the high levels of poverty category
[OR: 7.13 (4.36–11.66)], having three or more chronic
conditions [OR: 2.45 (1.33–4.5), p < 0.01], medium risk
for alcohol misuse [OR: 1.65 (1.11–2.45), p < 0.05], high
risk for alcohol misuse [OR: 2.76 (1.30–5.86), p < 0.01], to-
bacco use [OR: 2.30 (1.65–3.19), p < 0.001], having a part-
ner who is HIV positive [OR: 2.41 (1.75–3.32), p < 0.01],
and having sex in the past three months [OR: 1.44 (1.07–
1.93), p < 0.05].
The factors that are more likely to be associated with
adherence to dual therapy as indicated by the univariate
analysis are: being in the 35–44 year age group [OR:
0.68 (0.49–0.95), p < 0.05], having a grade 8 to 11 educa-
tion [OR: 0.66 (0.47–0.93), p < 0.05], perceiving health
status as being ‘poor’ [OR: 0.20 (0.14–0.29), p < 0.001],
perceiving health status to be ‘good’ [OR: 0.41 (0.28–
0.59), p < 0.001], being a new TB patient [OR: 0.51
(0.37–0.71), p < 0.001], and having a sex partner on ART
[OR: 0.51 (0.35–0.74), p < 0.001].
The results of the multivariate analysis as indicated
in Table 3 highlights the following significant predict-
ive factors for non-adherence to dual therapy in the
sub-sample of TB patients co-infected with HIV were:
medium poverty [OR: 2.60 (1.46–4.65), p < 0.001], high
levels of poverty [OR: 3.89 (1.87–8.12), p < 0.001],
having one (1) chronic condition [OR: 2.73 (1.31–5.65),
Table 3 Predictors of non-adherence to ART and anti-TB
medication (N = 757)
Socio-demographics Crude OR
(95% CI)
Adjusted OR
(95% CI)a,b
Age 18–34 1.00 1.00
Age 35–44 0.68 (0.49–0.95)* 0.63 (0.38–1.03)
Age 45 and older 1.12 (0.76–1.64) 0.90 (0.49–1.67)
Female 1.00 1.00
Male 1.61 (1.20–2.16)*** 1.49 (0.95–2.32)
Grade 7 or less 1.00 1.00
Grade 8–11 0.66 (0.47–0.93)* 1.13 (0.67–1.93)
Grade 12 or more 0.79 (0.53–1.17) 1.19 (0.65–2.18)
Poverty low 1.00 1.00
Poverty medium 3.14 (2.05–4.79)*** 2.60 (1.46–4.65)***
Poverty high 7.13 (4.36–11.66)*** 3.89 (1.87–8.12)***
Health variables
Perceived health status
Very good/good 1.00 1.00
Good 0.41 (0.28–0.59)*** 0.69 (0.40–1.17)
Fair/Poor 0.20 (0.14–0.29)*** 0.28 (0.17–0.49)***
TB retreatment patient 1.00 1.00
New TB patient 0.51 (0.37–0.71)*** 0.67 (0.42–1.07)
Chronic conditions
Zero 1.00 1.00
One 1.39 (0.91–2.12) 1.72 (1.01–2.94)*
Two 1.50 (0.87–2.58) 2.73 (1.31–5.65)**
Three or more 2.45 (1.33–0.45)** 5.33 (2.27–12.55)***
Severe psychological distress
(K≥ 30)
1.00 (0.72–1.37) –
Alcohol: low risk (AUDIT 0–7) 1.00 1.00
Medium (AUDIT 8–19) 1.65 (1.11–2.45)* 1.08 (0.56–2.09)
High (AUDIT 20–40) 2.76 (1.30–5.86)** 13.09 (2.96–57.99)*
Current tobacco use 2.30 (1.65–3.19)*** 1.44 (0.85–2.43)
Partner HIV negative/
unknown
1.00 1.00
Partner HIV positive 2.41 (1.75–3.32)*** 3.12 (1.84–5.29)***
Had sex in past 3 months 1.44 (1.07–1.93)* 1.48 (0.96–2.28)
Sex partner on ART 0.51 (0.35–0.74)*** 0.50 (0.25–0.97)*
*P < 0.05; ** P < 0.01; *** P < 0.001.
aUsing “enter” LR selection of variables.
bHosmer and Lemeshow Chi-square 13.14df8, 0.107; Cox and Snell R2 0.24;
Nagelkerke R2 0.33.
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[OR: 5.33 (2.27–12.55), p < 0.001], high risk for alcohol
misuse [OR: 13.09 (2.96–57.990), p < 0.05] and having
a partner who is HIV positive [OR: 3.12 (1.84–5.29),
p < 0.001].
Finally, the following predictive factors were associated
with adherence to dual therapy: perceiving health status asbeing ‘poor’ [OR: 0.20 (0.14–0.29), p < 0.001] and having a
sex partner on ART [OR: 0.50 (0.25–0.97), p < 0.05].
Discussion
The sub-sample of HIV positive patients on dual ther-
apy for TB and HIV infection, in this study, shared a
similar economic and alcohol misuse profile to the total
sample of TB infected patients. In addition, nearly 40%
of patients on dual therapy reported having a partner
who is HIV positive. Finally, the self-report of non-
adherence to dual therapy is high in this sub-sample
(42.4%) but comparable to the figures reported in the
literature [2]. Non-adherence to both ART and anti-TB
drugs are of concern in this sub-group. However, given
the fact that this sub-group has a dual infection re-
quires that they take two sets of drugs, which could
prove to be quite burdensome. The use of a multiple
drug regimen may also lead to drug reactions causing
unmanageable side-effects ultimately leading to treat-
ment default [28-30]. The complexity of the drug treat-
ment regimen and the impact on the daily lives of
these patients are also factors that are associated with
poor adherence in these patients [29,30]. Patients on
strict drug treatment programmes also have daily com-
peting “life demands” associated with work and family.
The four common predictive factors independently
associated with non-adherence to anti-TB drugs and to
dual therapy (i.e. ART and anti-TB drugs) were poverty,
having co-morbid disease conditions, being at risk for
alcohol misuse and having a HIV positive partner. This
finding is supported by existing literature on the rela-
tionship between the social determinants of health and
health outcome and/or the quality of life of individuals
with one or more disease condition [31,32]. In this
study non-adherent behavior for both anti-TB drugs
and ART was associated with a lack of economic re-
sources (poverty) and negative personal circumstances
(co-morbid conditions and a HIV positive partner).
Clearly the lack of social, personal and economic re-
sources is a barrier to adherence. Unfortunately, the lack
of resources, in particular poverty, has historically been
associated with TB onset [33]. It stands to reason, there-
fore, that being poor is a barrier to health promoting be-
havior, such as adhering to a treatment programme,
because individuals faced with economic restraints do
not have an enabling environment that facilitates behav-
ior that will lead to better health outcomes. Being poor,
having negative personal circumstances and engaging in
risky behavior such as alcohol misuse is likely to lead to
poor health outcomes as a consequence of treatment de-
fault [13,34]. It is plausible that patient mis-use of alco-
hol, in particular, may have led to poor and impaired
judgement [35,36] when making health decisions, such
as not adhering to their anti-TB medication.
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negative participants’ who were non-adherent to anti-TB
drugs and in a relationship with a HIV positive partner,
placed not only themselves but their partners at risk for
poor health outcomes. Inconsistent adherence to anti-
TB drugs may not only lead to MDR and XDR-TB but
may increase the risk of transmission of TB to others liv-
ing and working in close proximity. The HIV positive
patients, in this study, who were not adhering to dual
therapy, placed themselves at risk for drug resistance
which could in turn reduce their life-span. ART, taken in
accordance with treatment guidelines is known to pro-
long an HIV infected person’s life and the availability of
ART has led health professionals to re-conceptualize
HIV and AIDS as chronic medical conditions.
One additional factor, namely tobacco use, was inde-
pendently associated with non-adherence to TB treat-
ment drugs. Individuals who smoke tobacco may be
conceived of as having a personality with an “increased
risk profile” which makes them prone to engaging in un-
desirable behaviours regardless of the consequences
[35,36]. It is not surprising, therefore, that participant’s
adherence to anti-TB drugs in this study, was mediated
by tobacco smoking.
The common predictive factor independently associ-
ated with adherence to anti-TB drugs and to dual therapy
(i.e. ART and ant-TB drugs) was: perceiving health status
to be poor. This finding may seem counter-intuitive at
first glance. It is reasonable, however, that the partici-
pants who perceived that their health status was poor on
the basis that they had a “double-disease” burden of be-
ing infected with TB and HIV were more motivated to
take the medication which they know to be an effective
form of treatment. Knowledge of medical treatment effi-
cacy for a specific disease condition is known to influ-
ence the adherence behavior of the recipients of care [5].
Additional predictive factors for adherence to TB
treatment were: perceiving health status to be good and
being HIV negative. This finding is supported by the lit-
erature that reports on factors found to be influencing
adherence to medical treatment regimens for commu-
nicable and non-communicable diseases. Individuals
with a transient medical condition, that can be cured,
equipped with the knowledge that heeding to health care
practitioner’s suggested treatment regimens for cure are
more likely to adhere [37]. Of course there are numer-
ous other factors that may influence adherence to medi-
cation for a curable disease, such as TB. These factors
include knowing someone who was cured, the need to
maintain a good health status, and having a high level of
health literacy (such as knowledge of disease transmis-
sion as in the case of TB) [7,32].
The results indicate that there is a trend between
perceived health status and adherence in the anti-TBtreatment group and the dual treatment group. In the anti-
TB treatment group health status perceived to be good is
associated with adherence to treatment but this is not the
case in the smaller group receiving dual treatment.
Finally, the additional predictive factor for adherence
to dual therapy (i.e. anti-TB treatment and ART) was
having a sex partner on ART. Having a sex partner on
ART is in some way a protective factor for an individual
who is also on ART because of the sero-concordant na-
ture of the relationship. Both partners in this relation-
ship are able to support each other in an open manner
without fear of being stigmatized for being HIV positive
[38,39]. Non-disclosure of certain medical conditions,
such as having HIV or AIDS, is known to fuel the epi-
demic [40]. Consequently, one may assume that in
households where there is non-disclosure of HIV status,
the adherence to ART will be non-existent, poor or in-
consistent for fear of one’s HIV positive status being re-
vealed [41]. In essence social support has a positive
association with medical treatment adherence [42].
Conclusion
A major limitation of this study is that it is cross-sectional.
Ideally, the adherence patterns of TB patients and those
dually infected with HIV should be tracked over time in
order to better understand how the disease course(s) influ-
ences the patient’s willingness to co-operate with the pre-
scribed treatment. Despite this limitation, the results of
this study provide insight into the factors that are associ-
ated with non-adherence to treatment among TB patients
and those co-infected with HIV. Given the factors found to
be associated with non-adherence in this study, a compre-
hensive treatment programme using a patient-centred
model is indicated for TB patients attending public health
care clinics in SA [5]. This comprehensive treatment
programme being advocated should address structural fac-
tors (such as poverty); risky behaviours (such as alcohol
mis-use and tobacco use); and psycho-social well-being
(such as social relationship counseling on engaging with a
sero-discordant partner is indicated for TB patients [with
and without HIV]) and counseling related to perceived
health status and living with co-morbid health conditions).
The treatment care package needs to involve not only the
health sector but other relevant government sectors, such
as social development.
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